Friday, February 24, 2017 4:39:57 PM
The rumor does make some sense though. IPCI was developing Rexista, Regataton and PODRAS. That's what they been doing in the past year. The deal on all three does make sense for somebody who's looking to compete in the ADF market.
Companies like EGLT with their guardian technology, and here we have nPODDDS and PODRAS. A company like Novartis that's looking to enter NASH market and ADF market would no doubt be looking at these technologies including their deal with CNAT. CNAT got a 50 mill up front which took their stock from 2 to 5. Should Novartis decides to license CNAT's product they are entitled up to 650 million in milestone payment.
NASH and ADF is really heating up in the recent year, and any big pharma will want to set themselves up for profitable future.
Recent IPCI News
- Suspension de la négociation par l'Organisme canadien de réglementation des investissements - IPCI • PR Newswire (Canada) • 03/06/2024 12:55:00 PM
- Canadian Investment Regulatory Organization Trading Halt - IPCI • PR Newswire (Canada) • 03/06/2024 12:51:00 PM
FEATURED Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM
One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM